MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

MiNK Therapeutics, Inc.NASDAQ: INKT

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$36.07K, compared with -$50.77K a year earlier. Trailing-twelve-month gross profit was -$167.05K.

Context

  • Gross profit grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$36.07K or moves back toward the trailing-twelve-month quarterly average of -$41.76K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$36.07K+6.5% QoQ
Last fiscal yearDec 2025
-$181.75K+15.6% YoY
LTMMar 2026
-$167.05K+21.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.0%——
1 year+15.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(181.75K) USD
Year-over-year change
+15.6%

Gross Profit vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's LTM Mar 2026 gross profit of -$167.05K is the 7th highest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of +21.3% is the 4th highest of 8, against a peer median of -100.0%.
INKT Competitors Peer median
Gross Profit for INKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTVTvTv Therapeutics Inc.LTM Mar 2026$36.84M +736860.0%—100.0%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$18.15M +2281.5%—86.4%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 -100.0%——
GANXGain Therapeutics, Inc.LTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026-$79K -100.3%——
INKTMiNK Therapeutics, Inc.LTM Mar 2026-$167.05K +21.3%——
OSTXOS Therapies IncorporatedLTM Mar 2026-$362.39K -17280.8%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
Peer median (excluding INKT) $0-100.0%—93.2%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue77.96K121.75K204.62K215.44K181.75K
Gross Profit(77.96K)(121.75K)(204.62K)(215.44K)(181.75K)
Gross Margin—————
Research & Development13.97M23.12M15.49M6.34M5.76B
Selling, General & Admin4.56M7.71M7.43M4.1M6.73B
Operating Expenses18.53M30.83M22.72M10.43M12.31M
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
EBITDA(27.7M)(27.87M)(22.25M)(10.57M)(12.31M)
EBITDA Margin—————
Operating Income(18.61M)(30.95M)(22.92M)(10.65M)(12.49M)
Operating Margin—————
Interest Income2.43K253.32K463.26K172.57K180.25K
Interest Expense2.43M253.32K000
Other Income / Expenses(11.61M)2.96M463.25K(134.56K)(6.96K)
Income Before Tax(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Net Margin—————
EPS (Basic)(9.03)(8.31)(6.54)(2.90)(2.93)
EPS (Diluted)(9.03)(8.31)(6.54)(2.80)(2.93)
Weighted Avg Shares3.35M3.37M3.44M3.74M4.27M
Weighted Avg Shares (Diluted)3.35M3.37M3.44M3.86M4.27M

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.